IF 12.8
Q1 MEDICINE, RESEARCH & EXPERIMENTAL
引用次数: 0
摘要
在成人高血压患者中开展的 GMRx2 试验1 表明，12 周后，与几种双药组合（替米沙坦加氨氯地平、替米沙坦加吲达帕胺或氨氯地平加吲达帕胺）相比，低剂量单药组合替米沙坦、氨氯地平和吲达帕胺可显著降低血压水平。各组之间的不良反应没有差异。这种新型疗法可改善高血压控制。本文章由计算机程序翻译，如有差异，请以英文原文为准。
Single-pill combination therapy is the standard of care for hypertension, but it is time for the next step: Implementation.
The GMRx2 trial1 in adults with high blood pressure (BP) demonstrated that after 12 weeks, a low-dose single-pill combination of telmisartan, amlodipine, and indapamide significantly reduced BP levels compared to several dual combinations (telmisartan with amlodipine, telmisartan with indapamide, or amlodipine with indapamide). Adverse events did not differ between the groups. This novel therapeutic option could improve high BP control.
求助全文
通过发布文献求助，成功后即可免费获取论文全文。
去求助
来源期刊
Med
MEDICINE, RESEARCH & EXPERIMENTAL-
CiteScore
17.70
自引率
0.60%
发文量
102
期刊介绍：
Med is a flagship medical journal published monthly by Cell Press, the global publisher of trusted and authoritative science journals including Cell, Cancer Cell, and Cell Reports Medicine. Our mission is to advance clinical research and practice by providing a communication forum for the publication of clinical trial results, innovative observations from longitudinal cohorts, and pioneering discoveries about disease mechanisms. The journal also encourages thought-leadership discussions among biomedical researchers, physicians, and other health scientists and stakeholders. Our goal is to improve health worldwide sustainably and ethically.
Med publishes rigorously vetted original research and cutting-edge review and perspective articles on critical health issues globally and regionally. Our research section covers clinical case reports, first-in-human studies, large-scale clinical trials, population-based studies, as well as translational research work with the potential to change the course of medical research and improve clinical practice.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
